Literature DB >> 15477384

Hormone replacement therapy and cardiovascular disease: what went wrong and where do we go from here?

Raghvendra K Dubey1, Bruno Imthurn, Lefteris C Zacharia, Edwin K Jackson.   

Abstract

Observational studies in humans and experimental studies in animals and isolated cells supported the widely held belief that hormone replacement therapy protects the cardiovascular system from disease. To nearly everyone's astonishment, the Women's Health Initiative Study and the Heart and Estrogen/Progestin Replacement Study overturned the conclusion that hormone replacement therapy protects the cardiovascular system and, in fact, supported the opposite view that such therapy may actually increase the risk of cardiovascular disease. This review addresses 2 questions: what went wrong and where do we go from here?

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15477384     DOI： 10.1161/01.HYP.0000145988.95551.28

Source DB:  PubMed          Journal:  Hypertension        ISSN： 0194-911X            Impact factor:   10.190


  27 in total

Review 1.  Vascular effects of phytoestrogens and alternative menopausal hormone therapy in cardiovascular disease.

Authors:  V B Gencel; M M Benjamin; S N Bahou; R A Khalil
Journal:  Mini Rev Med Chem       Date:  2012-02       Impact factor: 3.862

Review 2.  Impact of sex hormone metabolism on the vascular effects of menopausal hormone therapy in cardiovascular disease.

Authors:  Durr-e-Nayab Masood; Emir C Roach; Katie G Beauregard; Raouf A Khalil
Journal:  Curr Drug Metab       Date:  2010-10       Impact factor: 3.731

3.  Single nucleotide polymorphisms of ERβ and coronary atherosclerotic disease in Chinese Han women.

Authors:  Chunyu Shen; Zhenglian Chen; Mohammed Mahmoodurrahman; Xinshan Chen
Journal:  Int J Clin Exp Pathol       Date:  2015-02-01

Review 4.  Hypertension in postmenopausal women: pathophysiology and treatment.

Authors:  Chiara Leuzzi; Maria Grazia Modena
Journal:  High Blood Press Cardiovasc Prev       Date:  2011-03-01

Review 5.  Potential approaches to enhance the effects of estrogen on senescent blood vessels and postmenopausal cardiovascular disease.

Authors:  Raouf A Khalil
Journal:  Cardiovasc Hematol Agents Med Chem       Date:  2010-01

6.  Estrogen, vascular estrogen receptor and hormone therapy in postmenopausal vascular disease.

Authors:  Raouf A Khalil
Journal:  Biochem Pharmacol       Date:  2013-10-04       Impact factor: 5.858

7.  Subtype-specific estrogen receptor-mediated vasodilator activity in the cephalic, thoracic, and abdominal vasculature of female rat.

Authors:  Ossama M Reslan; Zongzhi Yin; Graciliano R A do Nascimento; Raouf A Khalil
Journal:  J Cardiovasc Pharmacol       Date:  2013-07       Impact factor: 3.105

8.  Equilin displays similar endothelium-independent vasodilator potential to 17β-estradiol regardless of lower potential to inhibit calcium entry.

Authors:  Fernando P Filgueira; Núbia S Lobato; Denise L Nascimento; Graziela S Ceravolo; Fernanda R C Giachini; Victor V Lima; Ana Paula Dantas; Zuleica B Fortes; R Clinton Webb; Rita C Tostes; Maria Helena C Carvalho
Journal:  Steroids       Date:  2018-11-17       Impact factor: 2.668

Review 9.  Estrogenic compounds, estrogen receptors and vascular cell signaling in the aging blood vessels.

Authors:  Dia A Smiley; Raouf A Khalil
Journal:  Curr Med Chem       Date:  2009       Impact factor: 4.530

10.  Experimental benefits of sex hormones on vascular function and the outcome of hormone therapy in cardiovascular disease.

Authors:  Reagan L Ross; Michelle R Serock; Raouf A Khalil
Journal:  Curr Cardiol Rev       Date:  2008-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.